# Dataset 1
- **First author:** Lestat R. Ali  
- **Corresponding author(s):** Stephanie K. Dougan  
- **DOI:** [10.1158/1078-0432.CCR-23-1444](https://doi.org/10.1158/1078-0432.CCR-23-1444)  
- **Cancer type:** Pancreatic Ductal Adenocarcinoma (PDAC)  
- **Treatments:** Anti-PD-1 + Chemoradiation (CRT), CRT only  
- **Unique patients:** 3  
- **Sample types:** Blood, Tumor  
- **Timepoints:** Pre-Infusion, Post-Infusion 
- The dataset includes **gene expression**, **TCR**, and **metadata** files.

# Dataset 2
- **First author:** Ayse Bassez  
- **Corresponding author(s):** Diether Lambrechts, Ann Smeets 
- **DOI:** [https://doi.org/10.1038/s41591-021-01323-8](https://doi.org/10.1038/s41591-021-01323-8)
- **Cancer type:** Hormone receptor-positive or triple-negative breast cancer (TNBC)
- **Treatments:** Anti-PD-1 (Pembrolizumab) ± Neoadjuvant chemotherapy
- **Unique patients:** 42
- **Sample types:** Tumor
- **Timepoints:** Pre-Infusion, Post-Infusion
- The dataset includes gene expression, TCR, and metadata files.

# Dataset 3
- **First author:** Justina X. Caushi
- **Corresponding author(s):** Srinivasan Yegnasubramanian, Hongkai Ji, Drew M. Pardoll or Kellie N. Smith.
- **DOI:** [https://doi.org/10.1038/s41586-021-03752-4](https://doi.org/10.1038/s41586-021-03752-4)
- **Cancer type:** Non-small cell lung cancer (NSCLC)
- **Treatments:** Neoadjuvant anti–PD-1 therapy (Nivolumab)
- **Unique patients:** 16
- **Sample types:** Tumor, Blood, Normal Adjacent Tissue, Lymph Nodes
- **Timepoints:** 4 weeks post-treatment at time of surgery
- The dataset includes gene expression, TCR, and metadata files.

# Dataset 4
- **First author:** Ryan D. Chow
- **Corresponding author(s):** Ryan D. Chow, Eric Song, Alessandro D. Santin
- **DOI:** [https://doi.org/10.1158/2159-8290.CD-22-0686](https://doi.org/10.1158/2159-8290.CD-22-0686)
- **Cancer type:** Mismatch-repair–deficient (MMRd) endometrial carcinoma
- **Treatments:** Anti-PD-1 (Pembrolizumab)
- **Unique patients:** 24
- **Sample types:** Peripheral blood (PBMCs); tumor (bulk TCR used for tumor-reactive clone identification)
- **Timepoints:** Pre-treatment, On-treatment (Day 21, Day 42)
- The dataset includes gene expression, TCR, and metadata files.

# Dataset 5
- **First author:** Amelie Franken  
- **Corresponding author(s):** Diether Lambrechts
- **DOI:** [https://doi.org/10.1016/j.immuni.2024.02.007](https://doi.org/10.1016/j.immuni.2024.02.007)  
- **Cancer type:** Head and neck squamous cell carcinoma (HNSCC)
- **Treatments:** Anti-PD-L1 (Durvalumab) monotherapy; Anti-PD-L1 + Anti-CTLA4 (Durvalumab + Tremelimumab) combination therapy
- **Unique patients:** 20  
- **Sample types:** Tumour, Blood, Normal Adjacent Tissue, Lymph Nodes
- **Timepoints:** Pre-treatment / On-treatment (at time of surgery, 14 days post-infusion)
- The dataset includes **gene expression**, **TCR**, and **metadata** files.

# Dataset 6
- **First author:** Niloufar Khojandi
- **Corresponding author(s):** Ryan M Teague 
- **DOI:** [https://doi.org/10.1007/s00262-022-03263-9](https://doi.org/10.1007/s00262-022-03263-9)  
- **Cancer type:** Melanoma
- **Treatments:** Anti-PD-1 (Nivolumab) monotherapy; Anti-PD-1 + Anti-CTLA-4 (Nivolumab + Ipilimumab) combination therapy
- **Unique patients:** 2  
- **Sample types:** Blood
- **Timepoints:** Pre-treatment / On-treatment (3 weeks, 6 weeks post-infusion)
- The dataset includes **gene expression**, **TCR**, and **metadata** files.

# Dataset 7
- **First author:** Baolin Liu
- **Corresponding author(s):** Weidong Han & Zemin Zhang 
- **DOI:** [https://doi.org/10.1038/s43018-021-00292-8](https://doi.org/10.1038/s43018-021-00292-8)
- **Cancer type:** Non-small cell lung cancer (NSCLC)
- **Treatments:** Anti-PD-1 (Pembrolizumab) with chemotherapy
- **Unique patients:** 36 
- **Sample types:** Tumour, Lymph Nodes
- **Timepoints:** Pre-treatment, On-treatment (variable times ranging from 3 to 11 weeks)
- The dataset includes **gene expression**, **TCR**, and **metadata** files.

# Dataset 8
- **First author:** Adrienne M. Luoma
- **Corresponding author(s):** Jonathan D. Schoenfeld, and Kai W. Wucherpfennig
- **DOI:** [https://doi.org/10.1016/j.cell.2022.06.018](https://doi.org/10.1016/j.cell.2022.06.018)
- **Cancer type:** Head and neck squamous cell carcinoma (HNSCC)
- **Treatments:** Anti-PD-1 (Nivolumab) monotherapy; Anti-PD-1 + Anti-CTLA-4 (Nivolumab + Ipilimumab) combination therapy (neoadjuvant)
- **Unique patients:** 28 
- **Sample types:** Tumour, Blood
- **Timepoints:** Pre-treatment / On-treatment (Week 1, Week 3, Week 4 at tumour resection)
- The dataset includes **gene expression**, **TCR**, and **metadata** files.
